QuidelOrtho Corporation Common Stock (QDEL) Stock Price

QDELStock

$12.91−54.57%52W

Market Cap$885.31M

P/E—

PEG Ratio2.06

Div yield—

Beta0.83

QDEL Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-35.37%

Price vs S&P 500 (4W)20.20%

PEG Ratio2.06

VGM Score48.77

P/CF (Annual)8.42x

Book Value / Share (Quarterly)$25.99

P/TBV (Annual)11.89x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)-5.80%

Cash Flow / Share (Quarterly)$-3.09

Price vs S&P 500 (YTD)-66.72%

Gross Margin (TTM)44.60%

Net Profit Margin (TTM)-39.20%

EPS (TTM)$-15.40

10-Day Avg Trading Volume2.61M

EPS Excl Extra (TTM)$-15.40

Revenue Growth (5Y)10.44%

EPS (Annual)$-16.69

ROI (Annual)-24.76%

Gross Margin (Annual)46.67%

Net Profit Margin (5Y Avg)-11.45%

Cash / Share (Quarterly)$1.81

Revenue Growth QoQ (YoY)2.77%

ROA (Last FY)-19.62%

Revenue Growth TTM (YoY)-2.46%

EBITD / Share (TTM)$-9.40

ROE (5Y Avg)-16.05%

Operating Margin (TTM)-31.03%

Cash Flow / Share (Annual)$-1.22

P/B Ratio0.50x

P/B Ratio (Quarterly)0.70x

Net Income / Employee (Annual)$-174,100

EV / Revenue (TTM)1.37x

Net Interest Coverage (TTM)-5.28x

ROA (TTM)-18.40%

EV / EBITDA (TTM)123.41x

EPS Incl Extra (Annual)$-16.69

Current Ratio (Annual)1.50x

Quick Ratio (Quarterly)0.66x

3-Month Avg Trading Volume1.66M

52-Week Price Return-54.57%

EV / Free Cash Flow (Annual)10.05x

Revenue / Employee (TTM)$411,400

Tangible BV / Share (Quarterly)$1.95

P/S Ratio (Annual)0.32x

Asset Turnover (Annual)0.47x

52-Week High$35.58

Operating Margin (5Y Avg)-4.25%

EPS Excl Extra (Annual)$-16.69

CapEx CAGR (5Y)23.73%

Tangible BV CAGR (5Y)-9.58%

26-Week Price Return-25.46%

Quick Ratio (Annual)0.84x

13-Week Price Return-25.72%

Total Debt / Equity (Annual)1.38x

Current Ratio (Quarterly)1.39x

Enterprise Value$3.65B

Revenue / Share Growth (5Y)1.11%

Asset Turnover (TTM)0.47x

Book Value / Share Growth (5Y)-2.13%

Revenue / Employee (Annual)$420,000

Inventory Turnover (Annual)2.62x

Pretax Margin (Annual)-40.57%

Cash / Share (Annual)$2.50

3-Month Return Std Dev82.92%

Gross Margin (5Y Avg)55.37%

Net Income / Employee (TTM)$-161,300

EBITDA Interim CAGR (5Y)-6.37%

ROE (Last FY)-58.93%

Net Interest Coverage (Annual)-4.16x

EPS Basic Excl Extra (Annual)$-16.69

P/FCF (TTM)9.22x

Receivables Turnover (TTM)7.79x

EV / Free Cash Flow (TTM)27.81x

Total Debt / Equity (Quarterly)1.63x

EPS Incl Extra (TTM)$-15.40

Receivables Turnover (Annual)7.12x

ROI (TTM)-22.70%

P/S Ratio (TTM)0.33x

Pretax Margin (5Y Avg)-8.52%

Revenue / Share (Annual)$40.27

Tangible BV / Share (Annual)$3.70

Forward P/E9.12x

Price vs S&P 500 (52W)-70.11%

Year-to-Date Return-54.80%

5-Day Price Return-2.57%

EPS Normalized (Annual)$-16.69

ROA (5Y Avg)-3.30%

Net Profit Margin (Annual)-41.45%

Month-to-Date Return22.49%

Cash Flow / Share (TTM)$7.04

EBITD / Share (Annual)$-10.84

Operating Margin (Annual)-33.85%

LT Debt / Equity (Annual)1.29x

P/CF (TTM)156.79x

ROI (5Y Avg)-3.74%

LT Debt / Equity (Quarterly)1.43x

EPS Basic Excl Extra (TTM)$-15.40

P/TBV (Quarterly)14.74x

P/B Ratio (Annual)1.04x

Inventory Turnover (TTM)2.47x

Pretax Margin (TTM)-38.52%

Book Value / Share (Annual)$28.28

Price vs S&P 500 (13W)-28.40%

Beta0.83x

P/FCF (Annual)12.49x

Revenue / Share (TTM)$39.15

ROE (TTM)-55.30%

52-Week Low$9.92

vGradeC

gGradeC

mGradeC

vgmGradeC

QDEL Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Aug 6, 2026	-$0.05	$0.13	+374.61%(+$0.18)
Q1 2026	May 5, 2026	$0.36	-$0.04	-111.21%(-$0.40)
Q4 2025	Feb 11, 2026	$0.42	$0.46	+8.81%(+$0.04)
Q3 2025	Nov 5, 2025	$0.47	$0.80	+71.64%(+$0.33)
Q2 2025	Aug 5, 2025	$0.01	$0.12	+858.47%(+$0.11)

QDEL Analyst Recommendations

Jun 2026

Jul 2026

Aug 2026

Sep 2026

2.50

2.38

Industry Peers — In Vitro Diagnostics(18)

Symbol	Value Score	Growth Score	Momentum Score	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
QDELQuidelOrtho Corporation Common Stock	C	C	C	0.3x	-2.5%	44.6%	—	$12.91
IDXXIdexx Laboratories Inc	D	B	B	9.7x	12.8%	62.5%	14.3%	$560.36
LNTHLantheus Holdings, Inc	C	B	B	4.2x	2.4%	61.0%	40.7%	$99.70
NEOGNeogen Corp	C	C	A	2.9x	-0.3%	47.4%	—	$11.81
CLDXCelldex Therapeutics, Inc	F	F	C	13683.0x	-97.3%	17.6%	—	$27.53
NTLAIntellia Therapeutics, Inc	D	D	C	26.9x	12.6%	—	—	$11.42
ACHVAchieve Life Sciences, Inc.	F	F	B	36.8x	-89.3%	—	—	$6.38
MYGNMyriad Genetics Inc	C	C	D	0.5x	-3.2%	68.8%	—	$3.98
TKNOAlpha Teknova, Inc. Common Stock	D	C	B	8.7x	12.3%	34.6%	—	$7.08
NNNNAnbio Biotechnology Class A Ordinary Shares	F	C	F	34.0x	-5.7%	89.0%	—	$3.13
IMDXInsight Molecular Diagnostics Inc. Common Stock	F	D	C	59.0x	-60.8%	48.3%	—	$3.01
ICCCImmucell Corp	C	C	A	3.2x	8.5%	40.3%	—	$10.75
BMRABIOMERICA INC	B	D	B	1.9x	-16.2%	8.1%	—	$1.85
TRIBTrinity Biotech plc	B	D	C	0.1x	-16.6%	32.9%	—	$8.03
VNRXVolitionRx Limited	B	B	F	2.0x	86.3%	—	—	$0.18
CDIOCardio Diagnostics Holdings Inc. Common stock	—	D	C	345.9x	-25.9%	—	—	$1.69
QCLSQ/C Technologies, Inc. Common Stock	B	—	F	5.3x	—	24.7%	—	$0.54
VRAXVirax Biolabs Group Limited Ordinary Shares	—	B	F	156.9x	96.4%	62.0%	—	$1.45
CDIOWCardio Diagnostics Holdings Inc. Warrant	—	—	F	—	—	—	—	$0.01

About QuidelOrtho Corporation Common Stock

QuidelOrtho Corp develops and manufactures rapid diagnostic testing solutions, including immunoassay, molecular testing, clinical chemistry, and transfusion medicine products. The company operates globally across North America, Europe, the Middle East and Africa, China, and other markets, with North America generating the majority of its revenue.